Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-21
2006-02-21
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254030, C514S268000, C514S269000, C514S270000, C544S367000, C544S368000, C544S369000
Reexamination Certificate
active
07001909
ABSTRACT:
Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
REFERENCES:
patent: 4567264 (1986-01-01), Kluge et al.
patent: 6451798 (2002-09-01), Varkhedkar et al.
patent: 6552023 (2003-04-01), Zablocki et al.
patent: 6573264 (2003-06-01), Zablocki et al.
patent: WO 01/62744 (2001-08-01), None
Urbain, M. et al ‘Cardiovascular potential of piperazinoisopropanoloxy derivatives of pyridoxine’ CA 98:46434 (1983).
Berthold, R. et al ‘(Aryloxy)hydroxypropyl heterocycles’ CA 106:84635 (1987).
Shaiee, A. et al ‘Microbial synthesis of HIV protease inhibitors’ CA 125:114698 (1996).
Lloyd, R. Jr. ‘Drug-directed mutagenesis/drug-driven selection for lethal mutants’ CA 131:82953 (1999).
Dressman, BA et al ‘Aromatic and heterocyclic amides as HIV protease inhibitors’ CA 124:317888 (1996).
Berthold, R. et al ‘3-Aminopropoxyaryl derivatives’ CA 105:172505 (1986).
Fan, Y. et al ‘Syntheses of 1-(2-hydroxy-3-aryloxypropyl)-4-aryolpiperazines’ CA 108:5971 (1988).
Suzuki T et al: “Structure-activity relationship of newly synthesized quinoline derivatives for reversal of multidrug resistance in cancer.”, Journal of Chemistry, vol. 40, No. 13, 1997, pp. 2047-2052, XP000924067, the whole document, particularly p. 2049, table 2, compound 5.
Zacharowski K et al: “Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infaret size and cardiac troponin T release in the rat.” . European Journal of Pharmacology, vol. 418, No. 1-2, Apr. 20, 2001, pp. 105-110, XP002215620, the whole document.
Lopaschuk G D: “Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism”, The American Journal of Cardiology, vol 82, No. 5A, Sep. 3, 1997, pp. 14K-17K, XP002215621, the whole document.
Elzein Elfatih
Ibrahim Prabha
Palle Venkata
Rehder Kenneth S.
Shenk Kevin
CV Therapeutics Inc.
Hartrum J. Elin
Owens Amelia A.
LandOfFree
Substituted heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3709006